Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
recombinant porcine -likeuricase used as adrug to treat severegout .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word pegloticase.
Examples
-
Researchers at Duke University Medical Center and Savient Pharmaceuticals have recently conducted a phase II trial of a drug called pegloticase which shows great promise in reducing the level of uric acid in the blood to targets levels within a few hours.
-
Because it changed the application for its gout treatment pegloticase, Savient said the U.S.
-
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA(TM) (pegloticase), which was approved by the FDA on
Savient Pharmaceuticals Provides Business Update - Yahoo! Finance 2011
-
Indianapolis, Indiana have commenced regularly scheduled commercial manufacturing campaigns to build inventory of pegloticase and KRYSTEXXA.
Savient Pharmaceuticals Provides Business Update - Yahoo! Finance 2011
-
Company, has continued to manufacture pegloticase and has recently manufactured two batches of pegloticase which have met all specifications.
Savient Pharmaceuticals Provides Business Update - Yahoo! Finance 2011
-
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ pegloticase for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Yahoo! Finance 2011
-
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ pegloticase for the treatment of chronic gout in adult patients refractory to conventional therapy.
Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer - Yahoo! Finance 2011
-
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA (TM) (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy.
-
The decrease was primarily due to $2.0 million in lower manufacturing related expenses including $4.3 million of decreased technology transfer costs from our proposed secondary source supplier of pegloticase API as the majority of the work was completed in the prior year.
-
Completed the manufacture of three consecutive batches of pegloticase active pharmaceutical ingredient (API) drug substance at our third party contract manufacturer (CMO), in our effort to revert to the manufacturing process used to manufacture pegloticase API drug substance from our pivotal KRYSTEXXA?
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.